If I'm looking at the correct site, Thomson Reuters (reuters.com?) the analyst recommendations have NEA as a buy or outperform. They also believe earnings will be positive in Q4 2018.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025